Items Tagged ‘yondelis’

November 2nd, 2015

Yondelis® Approved for Treatment of Soft Tissue Sarcoma

By

The United States Food and Drug Administration (FDA) approved the chemotherapy agent, Yondelis® (trabectedin), for the treatment of liposarcoma and leiomyosarcoma—two types of soft-tissue sarcomas.1 The approval of Yondelis is for patients whose cancer is not able to be removed by surgery and/or has spread to distant sites in the body. This treatment is approved […]

View full entry

Tags: advanced, leimyosarcoma, liposarcoma, News, Sarcoma, Soft Tissue Sarcomas, trabectedin, yondelis


October 20th, 2015

Yondelis® Bests Standard Therapy in Liposarcoma and Leiomyosarcoma

By

The chemotherapy agent, Yondelis® (trabectedine), improves outcomes compared to the standard agent, DTIC (dacarbazine), in patients with advanced liposarcoma or leiomyosarcoma that has recurred or progressed following prior therapies. These results were recently published as a “rapid communication” in the Journal of Clinical Oncology. Liposarcoma and leiomyosarcoma are both types of soft-tissue sarcomas.  Soft tissue […]

View full entry

Tags: dacarbazine, DTIC, leiomyosarcoma, liposarcoma, News, Sarcoma, Soft Tissue Sarcomas, trabectedine, yondelis


February 4th, 2015

YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma

By

The U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for YONDELIS® (trabectedin) to treat patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes. YONDELIS® is a novel, multimodal, synthetically produced antitumor agent, originally derived from the sea squirt, Ecteinascidia turbinata. The anti-cancer medicine works […]

View full entry

Tags: General Sarcoma, News, Sarcoma, Soft Tissue Sarcomas, soft tissue sardcoma, trabectedin, yondelis